Strathspey Crown Holdings announces acquisition of Novus Via assets

Strathspey Crown Holdings LLC announced today the acquisition of the portfolio companies of Novus Via LP, a Nevada-based venture capital investment firm focused on end-stage development and commercialization of advanced electromagnetic and electrochemical technologies spanning healthcare, clean energy and coherent acoustics. The terms of the transaction were not disclosed.

Robert E. Grant, Chairman of Strathspey Crown Holdings LLC, said, "Novus Via LP brings tremendous intellectual property and technical capabilities into our firm, significantly accelerating our development efforts in medical-grade wearable technology. This transaction also marks our first diversification into advanced clean energy technologies and coherent acoustics. We welcome the management of Novus Via LP and its portfolio companies into the growing global family of Strathspey Crown companies."

Peter F. Capuciati, Manager and General Partner of Novus Via LP said, "We are very pleased to join the Strathspey Crown portfolio of companies. This transaction brings the Novus Via LP companies access to Strathspey's significant marketing and healthcare channel access, intellectual property, and public policy resources to advance their operating objectives." Capuciati went on to add, "Strathspey is uniquely positioned to lead the rapidly emerging field of medical-grade wearable technologies and we are proud to work together to accelerate this exciting field of development and commercialization."

Source:

Strathspey Crown Holdings LLC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New center established to bridge AI technology and healthcare applications